Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): Study protocol for a randomised controlled trial

Trials

Volumn 13, Issue , 2012, Pages

  Uzun, Sevim ^a   Djamin, Remco S ^a   Kluytmans, JanAJW ^a   Van't Veer, Nils E ^a   Ermens, Anton A M ^a   Pelle, Aline J ^b   Mulder, Paul ^c   van der Eerden, Menno M ^c   Aerts, JoachimGJV ^a,c  

^a AMPHIA HOSPITAL   (Netherlands)

^b TILBURG UNIVERSITY   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antibiotic resistance; COPD; COPD exacerbation; Long term treatment; Macrolide antibiotics

Indexed keywords

AZITHROMYCIN; PLACEBO;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; HUMAN; INFLAMMATION; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MORBIDITY; NONHUMAN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HUMANS; LUNG; NETHERLANDS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESEARCH DESIGN; RESPIRATORY TRACT INFECTIONS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861954925     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-13-82     Document Type: Article

References (40)

1. Lopez AD, Mathers CD, Ezzati M, et al. Global burden of disease and risk factors 2006, Washington (DC): World Bank, editors.
2. Snider GL. Chronic obstructive pulmonary disease: risk factors, pathophysiology and pathogenesis. Annu Rev Med 1989, 40:411-429. 10.1146/annurev.me.40.020189.002211, 2658758.
3. Curtis JL, Freeman CM, Hogg JC. The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research. Proc Am Thorac Soc 2007, 4:512-521. 10.1513/pats.200701-002FM, 2365762,2365762, 17878463.
4. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008, 8:183-192. 10.1038/nri2254, 18274560.
5. Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 2004, 117(Suppl 9A):5S-11S.
6. Parnham MJ. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005, 18:125-131. 10.1097/01.qco.0000160901.71813.fe, 15735416.
7. Kudoh S. Applying lessons learned in the treatment of diffuse panbronchiolitis to other chronic inflammatory diseases. Am J Med 2004, 117(Suppl 9A):12S-19S.
8. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998, 157:1829-1832.
9. Fujii T, Kadota J, Kawakami K, Iida K, Shirai R, Kaseda M, Kawamoto S, Kohno S. Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 1995, 50:1246-1252. 10.1136/thx.50.12.1246, 1021345, 8553295.
10. Ichikawa Y, Hotta M, Sumita S, Fujimoto K, Oizumi K. Reversible airway lesions in diffuse panbronchiolitis. Detection by high-resolution computed tomography. Chest 1995, 107:120-125.
11. Kadota J, Mukae H, Ishii H, Nagata T, Kaida H, Tomono K, Kohno S. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med 2003, 97:844-850. 10.1016/S0954-6111(03)00042-8, 12854636.
12. Shirai T, Sato A, Chida K. Effect of 14-membered ring macrolide therapy on chronic respiratory tract infections and polymorphonuclear leukocyte activity. Intern Med 1995, 34:469-474. 10.2169/internalmedicine.34.469, 7549126.
13. Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991, 58:145-149. 10.1159/000195915, 1745845.
14. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax 2006, 61:895-902. 10.1136/thx.2005.057950, 2104771, 16809416.
15. Hansen CR, Pressler T, Koch C, Hoiby N. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros 2005, 4:35-40. 10.1016/j.jcf.2004.09.001, 15752679.
16. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290:1749-1756. 10.1001/jama.290.13.1749, 14519709.
17. Pirzada OM, McGaw J, Taylor CJ, Everard ML. Improved lung function and body mass index associated with long-term use of macrolide antibiotics. J Cyst Fibros 2003, 2:69-71. 10.1016/S1569-1993(03)00021-3, 15463852.
18. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002, 360:978-984. 10.1016/S0140-6736(02)11081-6, 12383667.
19. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002, 57:212-216. 10.1136/thorax.57.3.212, 1746273, 11867823.
20. Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2004, 2:CD002203.
21. Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2011, Accessed February 28, 2012, at http://www.goldcopd.org, Global Initiative for Chronic Obstructive Lung Disease.
22. Banerjee D, Khair OA, Honeybourne D. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med 2005, 99:208-215. 10.1016/j.rmed.2004.06.009, 15715188.
23. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011, 365:689-698. 10.1056/NEJMoa1104623, 3220999, 21864166.
24. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008, 178:1139-1147. 10.1164/rccm.200801-145OC, 18723437.
25. Amsden GW. Advanced-generation macrolides: tissue-directed antibiotics. Int J Antimicrob Agents 2001, 18(Suppl 1):S11-S15.
26. Dunn CJ, Barradell LB. Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 1996, 51:483-505. 10.2165/00003495-199651030-00013, 8882383.
27. Daniel R. Simplified treatment of acute lower respiratory tract infection with azithromycin: a comparison with erythromycin and amoxycillin. European Azithromycin Study Group. J Int Med Res 1991, 19:373-383.
28. Schonwald S, Gunjaca M, Kolacny-Babic L, Car V, Gosev M. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J Antimicrob Chemother 1990, 25(Suppl A):123-126.
29. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991, 91:40S-45S.
30. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010, 65(Suppl 1):i1-i58. 10.1136/thx.2010.136119, 20627931.
31. Denollet J. DS14: standard assessment of negative affectivity, social inhibition, and Type D personality. Psychosom Med 2005, 67:89-97. 10.1097/01.psy.0000149256.81953.49, 15673629.
32. Denollet J, Pedersen SS, Ong AT, Erdman RA, Serruys PW, van Domburg RT. Social inhibition modulates the effect of negative emotions on cardiac prognosis following percutaneous coronary intervention in the drug-eluting stent era. Eur Heart J 2006, 27:171-177.
33. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370. 10.1111/j.1600-0447.1983.tb09716.x, 6880820.
34. Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med 1997, 27:363-370. 10.1017/S0033291796004382, 9089829.
35. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002, 52:69-77. 10.1016/S0022-3999(01)00296-3, 11832252.
36. Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34:220-233. 10.1097/00005650-199603000-00003, 8628042.
37. Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, Bullinger M, Kaasa S, Leplege A, Prieto L, Sullivan M. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998, 51:1171-1178. 10.1016/S0895-4356(98)00109-7, 9817135.
38. Ware JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995, 33:AS264-AS279.
39. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145:1321-1327.
40. Siafakas NM. Preventing exacerbations of COPD-advice from Hippocrates. N Engl J Med 2011, 365:753-754. 10.1056/NEJMe1106979, 21864170.